{"Clinical Trial ID": "NCT00545688", "Intervention": ["INTERVENTION 1:", "Trastuzumab+Docetaxel", "Neoadjuvant (preoperative) treatment: Participants received an infusion of trastuzumab IV at a charge dose of 8 mg/kg on the first day of cycle 1 (21 days) followed by a maintenance dose of 6 mg/kg on the first day of cycle 2-4 and a docetaxel IV infusion at an initial dose of 75 mg/m^2 on the first day of cycle 1 followed by 100 mg/m^2 on the first day of cycle 2-4, if no dose-limiting toxicity occurred.", "Adjuvant treatment (2 weeks post-operative): Participants received trastuzumab 6 mg/kg IV followed by FEC on day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from cycle 8 to cycle 17.", "INTERVENTION 2:", "Trastuzumab+Pertuzumab+Docetaxel", "Neoadjuvant (preoperative) treatment: Participants received an infusion of trastuzumab IV at a charge dose of 8 mg/kg and an infusion of pertuzumab IV at a charge dose of 840 mg on the first day of Cycle 1 (21 days) followed by a maintenance dose of 6 mg/kg trastuzumab and 420 mg pertuzumab on the first day of Cycle 2-4. The infusion of Docetaxel IV was administered at an initial dose of 75 mg/m^2 on the first day of Cycle 1 followed by 100 mg/m^2 on the first day of Cycle 2-4, if no dose-limiting toxicity occurred.", "Adjuvant treatment (2 weeks post-operative): Participants received trastuzumab 6 mg/kg IV followed by FEC on day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from cycle 8 to cycle 17."], "Eligibility": ["Incorporation criteria:", "Women, >=18 years of age;", "Locally advanced, inflammatory or invasive breast cancer at the early stage;", "- HER2 positive (HER2+++ by IHC or FISH/CISH+).", "- Exclusion criteria:", "- metastatic disease (stage IV) or bilateral breast cancer;", "Previous anticancer treatment or radiation therapy for malignancy;", "Other malignant diseases, other than in situ cervical cancer or basal cell cancer;", "Insulin-dependent diabetes;", "A clinically relevant cardiovascular disease."], "Results": ["Performance measures:", "Percentage of participants receiving a complete pathological response (CPR)", "PCR was defined as the absence of invasive neoplastic cells during microscopic examination of tumour residues after surgery after primary systemic treatment.", "Duration: Approximately 4 months after randomization after surgery or early withdrawal, whichever occurs first (surgery was performed within 2 weeks of cycle 4)", "Results 1:", "Title of the arm/group: Trastuzumab+Docetaxel", "Treatment: Participants received an infusion of trastuzumab IV at a loading dose of 8 mg/kg on day 1 of Cycle 1 (21 days) followed by a maintenance dose of 6 mg/kg on day 1 of Cycle 2-4 and an infusion of docetaxel IV at an initial dose of 75 mg/m^2 on day 1 of Cycle 1 followed by 100 mg/m^2 on day 1 of Cycle 2-4, if no dose-limiting toxicity was observed.", "Adjuvant treatment (2 weeks post-operative): Participants received trastuzumab 6 mg/kg IV followed by FEC on day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from cycle 8 to cycle 17.", "Total number of participants analysed: 107", "Type of measurement: Number", "Unit of measure: percentage of participants 29.0 (20.6 to 38.5)", "Results 2:", "Title of the arm/group: Trastuzumab+Pertuzumab+Docetaxel", "Treatment: Participants received infusion of trastuzumab IV at a loading dose of 8 mg/kg and infusion of pertuzumab IV at a loading dose of 840 mg on day 1 of cycle 1 (21 days) followed by a maintenance dose of 6 mg/kg of trastuzumab and 420 mg of pertuzumab on day 1 of cycles 2 to 4. The infusion of Docetaxel IV was administered at an initial dose of 75 mg/m^2 on day 1 of cycle 1 followed by 100 mg/m^2 on day 1 of cycles 2 to 4, if no dose-limiting toxicity occurred.", "Adjuvant treatment (2 weeks post-operative): Participants received trastuzumab 6 mg/kg IV followed by FEC on day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from cycle 8 to cycle 17.", "Total number of participants analysed: 107", "Type of measurement: Number", "Unit of measure: percentage of participants 45.8 (36.1 to 55.7)"], "Adverse Events": ["Undesirable Events 1:", "Total: 21/107 (19.63 per cent)", "Febrile neutropenia * 10/107 (9.35 %)", "Neutropenia * 1/107 (0.93%)", "Left ventricular dysfunction * 0/107 (0.00 %)", "Angine pectoris * 0/107 (0.00 %)", "Congestive heart failure * 0/107 (0.00 %)", "Diarrhoea * 2/107 (1.87%)", "Hernia abdominal choking * 0/107 (0.00 %)", "Hemorrhage of duodenal ulcers * 0/107 (0.00 %)", "Pyrexia * 1/107 (0.93%)", "Adverse Events 2:", "Total: 22/107 (20.56 per cent)", "Febrile neutropenia * 8/107 (7.48%)", "Neutropenia * 6/107 (5.61%)", "Left ventricular dysfunction * 3/107 (2.80%)", "Angina pectoris * 1/107 (0.93%)", "Congestive heart failure * 0/107 (0.00 %)", "Diarrhoea * 0/107 (0.00 %)", "Hernia strangled by abdomen * 1/107 (0.93%)", "Hemorrhage of duodenal ulcers * 0/107 (0.00 %)", "Pyrexia * 1/107 (0.93%)"]}